{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+3&page=5", "query": { "intervention": "Control Vaccine 3", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 539, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+3&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+3&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T05:52:03.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07734649", "title": "Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Immunization", "Human Metapneumovirus Immunization", "Healthy Volunteers" ], "interventions": [ { "name": "RSV+HMPV vaccine", "type": "BIOLOGICAL" }, { "name": "Control Vaccine 3", "type": "BIOLOGICAL" }, { "name": "Control Vaccine 4", "type": "BIOLOGICAL" }, { "name": "Control Vaccine 2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Control Vaccine 1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 2400, "start_date": "2026-07-22", "completion_date": "2028-05-03", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 50, "location_summary": "Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more", "locations": [ { "city": "Gadsden", "state": "Alabama" }, { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07734649" }, { "nct_id": "NCT03409276", "title": "Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "gp120 (A,B,C,A/E) Protein Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2018-03-16", "completion_date": "2020-10-22", "has_results": true, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409276" }, { "nct_id": "NCT07095868", "title": "Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Selected Types of Solid Tumor" ], "interventions": [ { "name": "EVM14", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Everest Medicines (Beijing) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2025-11-17", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas • Fairfax, Virginia", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07095868" }, { "nct_id": "NCT07801456", "title": "A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cytomegalovirus (CMV)", "HIV (Human Immunodeficiency Virus)" ], "interventions": [ { "name": "VIR-1388", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2026-10-15", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Boston, Massachusetts", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07801456" }, { "nct_id": "NCT02362451", "title": "Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Cancer" ], "interventions": [ { "name": "Autologus elutriated monocyte placebo vaccine", "type": "BIOLOGICAL" }, { "name": "Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 7, "start_date": "2015-07-10", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02362451" }, { "nct_id": "NCT03950622", "title": "Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1205, "start_date": "2019-06-13", "completion_date": "2020-03-30", "has_results": true, "last_update_posted_date": "2021-04-26", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 14, "location_summary": "Mesa, Arizona • San Diego, California • Hialeah, Florida + 10 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950622" }, { "nct_id": "NCT00679172", "title": "Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Typhoid" ], "interventions": [ { "name": "Dose of 5.0 x 10^9 CFU (Cohort 1)", "type": "BIOLOGICAL" }, { "name": "Dose of 7.5 x 10^9 CFU (Cohort 2)", "type": "BIOLOGICAL" }, { "name": "Dose of 1.1 x 10^10 CFU (Cohort 3)", "type": "BIOLOGICAL" }, { "name": "Dose of of 1.7 x 10^10 CFU (Cohort 4)", "type": "BIOLOGICAL" }, { "name": "Placebo (Cohorts 1-4 pooled)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Emergent BioSolutions", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 187, "start_date": "2008-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 3, "location_summary": "South Miami, Florida • Baltimore, Maryland • Burlington, Vermont", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00679172" }, { "nct_id": "NCT04451954", "title": "Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza Immunisation", "Healthy Volunteers" ], "interventions": [ { "name": "Quadrivalent RIV with H3 strain 1", "type": "BIOLOGICAL" }, { "name": "Quadrivalent RIV with H3 strain 1 and adjuvant", "type": "BIOLOGICAL" }, { "name": "Quadrivalent RIV with H3 strain 2", "type": "BIOLOGICAL" }, { "name": "Quadrivalent RIV with H3 strain 2 and adjuvant", "type": "BIOLOGICAL" }, { "name": "Quadrivalent RIV with 2018-2019 NH H3 strain", "type": "BIOLOGICAL" }, { "name": "Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2020-07-02", "completion_date": "2021-09-20", "has_results": false, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 5, "location_summary": "San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04451954" }, { "nct_id": "NCT02561871", "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Viruses", "Respiratory Tract Infections" ], "interventions": [ { "name": "Ad26.RSV.FA2", "type": "BIOLOGICAL" }, { "name": "Ad35.RSV.FA2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Crucell Holland BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 34, "start_date": "2015-09", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-11-01", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02561871" }, { "nct_id": "NCT01424644", "title": "A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Meningococcal Meningitis" ], "interventions": [ { "name": "Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine", "type": "BIOLOGICAL" }, { "name": "MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "11 Years to 18 Years" }, "enrollment_count": 801, "start_date": "2011-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-10-17T05:52:03.022Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Fremont, California • Madera, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fremont", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Dayton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01424644" } ] }